FDA Approves Chewable Tablet for Canine Parasite Protection

The FDA has approved afoxolaner, moxidectin, and pyrantel chewable tablets, known as NexGard PLUS from Boehringer Ingelheim, to protect dogs from fleas, ticks, heartworm disease, roundworms, and hookworms. These monthly chewable tablets feature a beef flavor to enhance compliance among pet owners.

Daniel Watkins, MBA, vice president of US Pet at Boehringer Ingelheim Animal Health, emphasized the company's commitment to simplifying pet care. He noted that NexGard PLUS broadens their parasiticide offerings, enabling veterinarians to prescribe tailored products for each pet's needs.

Parasitic threats are increasingly common, with certain tick species expanding into new regions and the incidence of heartworm disease rising across the United States. The Companion Animal Parasite Council advises pet owners to use year-round broad-spectrum parasite control to combat these risks effectively.

Boehringer Ingelheim asserts that clinical studies confirm the safety and efficacy of NexGard PLUS against parasites. Veterinarians can opt for 3-dose and 6-dose presentation options to better serve the needs of their patients.

Whit Cothern, DVM, executive director of veterinary professional services at Boehringer Ingelheim, stated the advantage of NexGard PLUS in providing both internal and external parasite protection with a single chewable. The new product will be available to veterinary practices starting July 31, 2023.